Physician profile
Michael H Phillips
NPI 1699811349
$2,411.32
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $787 · 2021: $267 · 2022: $286.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,198.92 | 2019-2020 | |
| Procept Biorobotics Corporation | $422.85 | 2019-2022 | |
| Boston Scientific Corporation | $228.39 | 2019-2022 | |
| Allergan, INC. | $107.29 | 2019-2021 | |
| Astellas Pharma US INC | $102.58 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $96.84 | 2019-2020 | |
| Myovant Sciences INC. | $79.23 | 2021 | |
| Urogen Pharma, INC. | $43.60 | 2021 | |
| Antares Pharma, INC. | $40.78 | 2022 | |
| Amgen INC. | $23.89 | 2021 | |
| Olympus America INC. | $19.76 | 2021 | |
| Abbvie INC. | $17.08 | 2022 | |
| Janssen Biotech, INC. | $16.87 | 2019 | |
| Teleflex LLC | $13.24 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.